MUSTANG BIO, INC. current report, 17 May 2023

Full document

Business Context and Reporting Period

Company: Mustang Bio, Inc. (MBIO)
Filing Type: Form 8-K (Current Report)
Date of Report: May 17, 2023 (Earliest event reported)
Reporting Period: Immediate events occurring May 17–18, 2023.

Mustang Bio, a clinical-stage biopharmaceutical company, announced a strategic restructuring involving the sale of its Worcester, Massachusetts cell processing facility, the discontinuation of four CAR T-cell therapy programs, and a significant workforce reduction. The company also provided updates on its XSCID gene therapy program and confirmed compliance with Nasdaq listing requirements.

Key Financial Metrics and Transaction Details

Facility Sale Transaction:

  • Total Purchase Price: $11,000,000.
  • Base Amount: $6,000,000 (payable upon closing).
  • Contingent Amount: $5,000,000 (payable only if the Company raises $\ge$10,000,000 in equity within two years of closing).
  • Buyer: uBriGene (Boston) Biosciences, Inc. (a subsidiary of a Chinese CDMO).

Manufacturing Commitment:

  • Minimum Commitment: Company to spend at least $8,000,000 over two years on manufacturing services from uBriGene.
  • Rebate: Potential cash rebate up to $3,000,000 if spending exceeds the minimum commitment.

Restructuring Costs and Savings:

  • One-Time Expenses: Approximately $2.9 million total ($2.1 million cash severance; $0.8 million non-cash equity expense).
  • Expected Annualized Savings: Approximately $24 million from facility sale, program discontinuation, and workforce reduction.

Liquidity and Debt: The filing does not provide specific current cash balances, debt levels, or liquidity metrics. The contingent sale consideration is tied to a future capital raise.

Material Changes Versus Prior Period

  • Asset Disposition: Agreement to sell the primary cell processing facility and associated assets, shifting from in-house manufacturing to a contract manufacturing model.
  • Portfolio Reduction: Termination of four CAR T-cell programs (MB-102, MB-103, MB-104, MB-105) developed in partnership with City of Hope. No early termination penalties apply.
  • Workforce Reduction: Board approved a reduction of approximately 82% of the workforce. At least 40 employees are expected to transfer to uBriGene.
  • Regulatory Status: Regained compliance with Nasdaq Minimum Bid Price Rule 5550(a)(2) as of April 19, 2023.

Guidance, Outlook, Risks, and Unusual Items

Outlook and Management Commentary:

  • Strategic Focus: The company is consolidating resources to focus on lead product candidates, specifically MB-106 and the XSCID program.
  • XSCID Program: Enrollment in investigator-sponsored trials has been paused. The company will delay its own sponsored trials to await data on a modified lentiviral vector to ensure safety. No safety concerns or malignancies have been detected to date.
  • CFIUS Review: The transaction involves a voluntary notice to the U.S. Committee on Foreign Investment in the United States (CFIUS). Clearance is not a condition to closing, but CFIUS may impose mitigation measures (e.g., divestiture, compliance personnel) post-closing.

Risks and Contingencies:

  • Closing Conditions: The sale is subject to landlord consent for lease assignment, acceptance of employment by four key employees, and customary representations. The "Outside Date" for closing is June 30, 2023.
  • Contingent Consideration Risk: The $5 million contingent payment is at risk if the company fails to raise $10 million in equity within two years.
  • Operational Transition: Risks associated with transitioning manufacturing to uBriGene and potential disruption to business relationships.

Important Facts for Investor Verification

  • Capital Raise Requirement: Verify the company's ability to raise $10 million in equity within two years to secure the $5 million contingent portion of the facility sale.
  • CFIUS Outcome: Monitor the CFIUS review process to determine if mitigation measures are imposed that could impact operations or require divestiture.
  • Manufacturing Continuity: Confirm that uBriGene successfully assumes the lease and maintains the facility's operational capacity for MB-106 production.
  • XSCID Timeline: Track the release of data from the modified vector trials to understand the revised timeline for the company's sponsored XSCID trials.
  • Cost Realization: Verify the actual realization of the projected $24 million in annualized operating savings against the $2.9 million in immediate restructuring costs.